PASADENA, Calif.--(BUSINESS WIRE)--Aug. 11, 2006--Calando Pharmaceuticals Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), today announced the appointment of Dr. Jeremy D. Heidel as Chief Scientific Officer and Vice President of Research and Development for the company. Heidel will work with Calando’s management team to set the strategic direction of Calando’s research and development functions and help drive its growth strategies in the emerging area of the therapeutic use of RNA interference, or “RNAi.”
